The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review

Table 2 Intervention characteristics

First author	Type of HT	Dose of HT	Route of HT	Duration of HT^a-mean (range/SD)^b
Challberg [33]	ET, EPT and tibolone	NS	NS	3.4 (0.1-19)
Chapman [37]	NS	NS	NS	6 (0.75-9)
Eisen [21]	ET and EPT	NS	NS	3.85^c (NS)
Finch [38]	ET and EPT	NS	NS	NS
Gabriel [28]	ET and EPT	NS	NS	2.79 ± 3.22
Garcia [30]	NS	NS	Systemic HT (60%)	NS
Heiniger [29]	NS	NS	NS	NS
Johansen [36]	ET, EPT and tibolone	NS	Systemic HT (39.28%) & local/vaginal HT (6.54%)	NS
Kotsopoulos [31]	ET and EPT	NS	NS	4.35(0.05-25)^c
Madalinska [34]	EPT and tibolone	NS (standard)	Systemic HT (Oral/transdermal)	3 ± 2.3
Michelsen [35]	NS	NS	Systemic (Oral/transdermal)	NS
Rebbeck [20]	ET and EPT	NS	NS	NS
Tucker [32]	ET	NS	Systemic HT (20% - oral and transdermal) & local/vaginal HT (8%)	NS

HT hormone therapy, ET estrogen therapy, EPT estrogen-progestogen therapy, NS not specified
^ain years; ^bbased on the measure of variance reported in the primary study; ^caverage duration of use among cases and controls

ISSN: 1472-6874